Loading...
Market
Who will most strongly oppose obesity drug coverage expansion by June 2025?
2
Biden•Medicare•Medicaid•Wegovy•Ozempic•Zepbound•Americans•Congress•Gwen Moore•Raul Ruiz•Novo Nordisk•Eli Lilly
Resolution / Starting Odds
Pharmaceutical Companies • 25%
Insurance Companies • 25%
Healthcare Providers • 25%
Political Groups • 25%
Public statements, lobbying records, or policy analysis reports
Story
Biden Proposes Medicare, Medicaid Cover Obesity Drugs Like Wegovy for Over 7 Million Americans
Nov 26, 2024, 02:41 PM
The Biden administration has proposed expanding Medicare and Medicaid coverage to include anti-obesity medications, such as Wegovy, Ozempic, and Zepbound. This initiative aims to recognize obesity as a treatable disease and would potentially make these medications accessible to 3.4 million Americans with Medicare and 4 million Americans with Medicaid who are living with obesity. The proposed expansion could reduce out-of-pocket expenses for some individuals by up to 95% and is estimated to cost taxpayers approximately $35 billion over the next nine years. The plan has garnered support from bipartisan members of Congress, including Representatives Gwen Moore and Raul Ruiz, and is seen as a significant step toward addressing obesity as a public health issue. Following the announcement, shares of weight-loss drug makers Novo Nordisk and Eli Lilly rose.
View original story
Similar markets
Eli Lilly • 33%
Novo Nordisk • 33%
Both equally • 34%
Yes • 50%
No • 50%
Approved as proposed • 25%
Approved with modifications • 25%
Rejected • 25%
No decision by deadline • 25%
Financial cost • 25%
Drug efficacy • 25%
Off-label use • 25%
Availability/shortages • 25%
Novo Nordisk • 25%
Eli Lilly • 25%
Pfizer • 25%
Other • 25%
Cost concerns • 25%
Public health benefits • 25%
Lobbying influence • 25%
Other • 25%
Novo Nordisk • 25%
Eli Lilly • 25%
Other • 25%
None • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Pfizer • 25%
Merck • 25%
Johnson & Johnson • 25%
Other • 25%
MariTide leads market share • 25%
Eli Lilly leads market share • 25%
Novo Nordisk leads market share • 25%
Market share is evenly distributed • 25%
Roche's CT-996 has the largest market share • 25%
Novo Nordisk has the largest market share • 25%
Eli Lilly has the largest market share • 25%
Other companies have the largest market share • 25%